London, UK, 27 September 2006 - Ark Therapeutics Group plc (‘Ark’ or the ' Company’) today announces that it is to launch Flaminal(R), a topical anti-microbial wound care gel, in the UK on 1st October. Flaminal(R) will be sold to hospitals and community nurses through Ark’s existing UK salesforce which currently promotes Kerraboot(R), the Company’s novel device for the treatment of diabetic and venous leg ulcers. The launch follows Ark’s success in securing price reimbursement from the UK NHS Business Service Authority, announced earlier in the year.
